Jiangsu Hengrui Medicine Co Ltd Capital Reinvestment Ratio
Jiangsu Hengrui Medicine Co Ltd capital reinvestment ratio. Jiangsu Hengrui Medicine Co Ltd (600276) has a Capital Reinvestment Ratio of 0.09x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥4.81 Billion) in capital expenditures (CN¥446.90 Million). See Jiangsu Hengrui Medicine Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Jiangsu Hengrui Medicine Co Ltd (1999–2024)
Capital reinvestment ratio of Jiangsu Hengrui Medicine Co Ltd from 1999 to 2024. This chart tracks Jiangsu Hengrui Medicine Co Ltd's Capital Reinvestment Ratio across 26 annual periods. See 600276 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Jiangsu Hengrui Medicine Co Ltd Capital Reinvestment Ratio by Year (1999–2024)
Jiangsu Hengrui Medicine Co Ltd capital reinvestment ratio by year from 1999 to 2024. For the full cash flow conversion analysis, see Jiangsu Hengrui Medicine Co Ltd (600276) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | CN¥7.42 Billion | CN¥1.97 Billion | ▲ +36.7% |
| 2023 | 0.19x | CN¥7.64 Billion | CN¥1.48 Billion | ▼ -87.7% |
| 2022 | 1.57x | CN¥1.27 Billion | CN¥1.99 Billion | ▲ +299.0% |
| 2021 | 0.39x | CN¥4.22 Billion | CN¥1.66 Billion | ▲ +144.3% |
| 2020 | 0.16x | CN¥3.43 Billion | CN¥554.33 Million | ▲ +9.8% |
| 2019 | 0.15x | CN¥3.82 Billion | CN¥561.35 Million | ▼ -22.9% |
| 2018 | 0.19x | CN¥2.77 Billion | CN¥529.11 Million | ▲ +27.8% |
| 2017 | 0.15x | CN¥2.55 Billion | CN¥380.30 Million | ▼ -65.2% |
| 2016 | 0.43x | CN¥2.59 Billion | CN¥1.11 Billion | ▲ +147.6% |
| 2015 | 0.17x | CN¥2.28 Billion | CN¥394.09 Million | ▼ -8.7% |
| 2014 | 0.19x | CN¥1.57 Billion | CN¥298.52 Million | ▼ -42.9% |
| 2013 | 0.33x | CN¥1.36 Billion | CN¥453.30 Million | ▼ -31.8% |
| 2012 | 0.49x | CN¥958.37 Million | CN¥466.83 Million | ▼ -52.5% |
| 2011 | 1.02x | CN¥527.36 Million | CN¥540.27 Million | ▲ +37.9% |
| 2010 | 0.74x | CN¥385.95 Million | CN¥286.73 Million | ▲ +130.3% |
| 2009 | 0.32x | CN¥439.12 Million | CN¥141.65 Million | ▼ -65.9% |
| 2008 | 0.95x | CN¥117.46 Million | CN¥111.21 Million | ▲ +210.0% |
| 2007 | 0.31x | CN¥218.87 Million | CN¥66.85 Million | ▼ -5.8% |
| 2006 | 0.32x | CN¥266.18 Million | CN¥86.29 Million | ▲ +17.1% |
| 2005 | 0.28x | CN¥227.88 Million | CN¥63.07 Million | ▼ -26.7% |
| 2004 | 0.38x | CN¥209.41 Million | CN¥79.11 Million | ▼ -76.1% |
| 2003 | 1.58x | CN¥136.82 Million | CN¥216.62 Million | ▼ -35.8% |
| 2002 | 2.47x | CN¥49.84 Million | CN¥122.90 Million | ▼ -89.7% |
| 2001 | 23.99x | CN¥11.49 Million | CN¥275.58 Million | ▲ +478.2% |
| 2000 | 4.15x | CN¥19.61 Million | CN¥81.34 Million | ▲ +591.8% |
| 1999 | 0.60x | CN¥33.89 Million | CN¥20.32 Million | — |